Kowa says FDA accepts NDA for glaucoma drug K-911 for review

• Kowa Pharmaceuticals America secured FDA acceptance for review of its NDA for K-911 eye drop for open-angle glaucoma, ocular hypertension.
• FDA set a PDUFA target action date of April 30, 2027.
• US launch is expected in the second half of 2027, pending approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kowa Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608271103PR_NEWS_USPR_____NY34803) on August 27, 2026, and is solely responsible for the information contained therein.